Alimera, pSivida plummet on 3rd FDA Iluvien rejection
This article was originally published in Scrip
Executive Summary
Alimera Sciences and its partner pSivida both plummeted just over 39% on 18 October on word the FDA for the third time had refused to give its blessing to the companies' Iluvien (fluocinolone acetonide intravitreal insert) as a treatment for diabetic macular edema (DME).